President and Independent Consultant, Pharmasagacity Consulting, LLC
Russell L. Barton
After over 38 years working for Eli Lilly & Company, Russell (Russ) retired from Lilly at the end of December 2017. Russ' first 13 years at Lilly were spent in Discovery Chemistry actively working in the lab involved in immunology, inflammation, and oncology research. Leaving the lab and moving into Pharmaceutical Project Management, Russ spent the remaining 25 years at Lilly leading many drug development projects in stages from Preclinicial through Phase 4. Now retired from Lilly, Russ has a passion for utilizing his extensive experience to benefit drug development projects to enable solutions for patients and value for organizations.
During the 25+ years leading development teams at Lilly from 1992 through 2017, Russ had roles as (time ordered):
Program Team Leader for early phase projects in Alzheimer's Disease (symptomatic treatment), AMPA and NMDA antagonists, and Parkinson's Disease
Chief Operations Officer for the product team supporting a launched late lifecycle PD drug, including transdermal development, based in the UK
Chief Operations Officer for the product team supporting Phase 3 through initial market authorization submissions for an ADHD drug
Chief Operations Officer for the product team supporting a launched mid-to-late lifecycle atypical antipsychotic drug
Chief Operations Officer for a NS Platform Team providing global team support of all launched NS drugs
Chief Operations Officer for the Global Alzheimer's Platform team which was responsible for strategy and implementation of Phase 3 development of a small molecule and mAb targeting slowing of disease progression
Neuroscience Project Management Therapeutic Area Liaison and Program Team Leader for early phase Alzheimer's Disease projects
Russ had extensive experience in Neuroscience projects while at Lilly. During this 25 year period he also had ongoing active shared learning with peers in other therapeutic areas.
Since starting PharmaSagacity Consulting, Russ has experience consulting with a variety of pharma companies, from Large Pharma to Small Biotech.
In addition to selected consulting work, Russ is currently the Director of Clinical Operations for AgeneBio and the IND and Clinical Operations Leader for Acumen Pharmaceuticals.
Curriculum Vitae available upon request.
Operational Leadership in Many Global Regulatory Submissions
Submissions of New Molecular Entities, Line Extensions, and New Indications for multiple products in all major regions across the globe.
Participation in External Alzheimer's Disease Efforts
Russ was an original pharma member of the Global Alzheimer's Platform public/private partnership, serving for 3 years as a co-chair of the working group that has ultimately become GAP-Net.
Link to co-authored publication "RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK".
Affiliation with Alzheimer's Disease Drug Development Experts
Russ has affiliations with additional Alzheimer's disease experts in other drug development functional areas. Russ and the AD experts below have worked together for over a decade providing knowledgeable support for candidate therapeutics. These consultants are available individually or can be engaged as a high functioning team.
Robert Dean, PhD MD: Biomarker-based drug and diagnostic R&D.
Douglas Everidge, BS: New product planning, strategic marketing, brand development.
Janice Hitchcock, PhD: Regulatory strategy including early and late phase regulatory interactions.
Eric Siemers, MD: Translational medicine including early and late phase clinical trial design.
Karen Sundell, BS: Bioclinical data design, translation, processing, strategy and communication.